Robert Eriksson
Datos Biográficos
| ID | 7958751 |
|---|---|
| NOMBRE | Robert Eriksson |
| NOMBRES | Robert |
| APELLIDO | Eriksson |
| FIRMA | ERIKSSON R |
| AFILIACIONES | Copenhagen University Hospital |
| ORCID | 0000-0002-4946-6456 |
| VERIFICADO | Sí |
| TOTAL DE OBRAS | 1 |
| TOTAL DE CITAS | 0 |
| OBRAS COMO AUTOR | 1 |
| OBRAS COMO EDITOR | 0 |
| PRIMER AÑO DE PUBLICACIÓN | 2019 |
| AÑO MÁS RECIENTE DE PUBLICACIÓN | 2019 |
| ÍNDICE H | 0 |
Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density
Background: Low bone mineral density (BMD) may constitute an underestimated comorbidity in schizophrenia patients undergoing long-term antipsychotic treatment. Glucagon-like peptide 1 (GLP-1) receptor agonists are antidiabetic drugs, which may also affect bone turnover. Methods: In planned secondary analyses of a 3 months, double-blind, randomized, placebo-controlled trial ( n = 45), we explored effects of the GLP-1 receptor agonist exenatide 2 m…
Sin obras prominentes en esta página.
Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density
Background: Low bone mineral density (BMD) may constitute an underestimated comorbidity in schizophrenia patients undergoing long-term antipsychotic treatment. Glucagon-like peptide 1 (GLP-1) receptor agonists are antidiabetic drugs, which may also affect bone turnover. Methods: In planned secondary analyses of a 3 months, double-blind, randomized, placebo-controlled trial ( n = 45), we explored effects of the GLP-1 receptor agonist exenatide 2 m…
Agonist (1 obra) · Antipsychotic (1 obra) · Biochemistry (1 obra) · Bone density (1 obra) · Bone mineral (1 obra) · Bone remodeling (1 obra) · Chemistry (1 obra) · Diabetes mellitus (1 obra) · Diabetes Treatment and Management (1 obra) · Diet and metabolism studies (1 obra)